PEER REVIEWED JOURNAL ARTICLES AND ABSTRACTS

  1. Nosrati A, Ch'en PY, Torpey ME, Shokrian N, Ball G, Benesh G, Andriano TM, Zhu TR, Heibel HD, Hosgood HD, Campton KL, Cohen SR. Efficacy and Durability of Intravenous Ertapenem Therapy for Recalcitrant Hidradenitis Suppurativa. JAMA Dermatol. 2024 Feb 14.

  2. Nosrati A, Torpey ME, Andriano TM, et al. Importance of a multi-tiered treatment approach for intellectually and developmentally disabled patients with hidradenitis suppurativa. Arch Dermatol Res. 315, 1827–1829 (2023).

  3. Nosrati A, Torpey ME, Shokrian N, Ch’en PY, Andriano TM, Benesh G, et al. Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa. Int J Dermatol. 2022; doi: 10.1111/ijd.16565.

  4. Nosrati A, Torpey ME, Ball GD, Shokrian N, Campton KL, Cohen SR. COVID-19 vaccine immunity in hidradenitis suppurativa patients receiving TNF-alpha inhibitors. J Invest Dermatol. 2022; 142(8):B12.

  5. Nosrati A, Torpey ME, Andriano TM, Ch’en PY Dervieux T, Campton KL, Cohen SR. Association of hidradenitis suppurativa with a Crohn’s disease panel. J Invest Dermatol. 2022; 142(8):S35.

  6. Nosrati A, Torpey ME, Campton KL, Cohen SR. Mental health professional utilization within a cohort of hidradenitis suppurativa patients. J Invest Dermatol. 2022; 142(8):B13.

  7. Nosrati A, Torpey ME, Campton KL, Cohen SR. Opioid use disorder in a cohort of hidradenitis suppurativa patients. J Invest Dermatol. 2022; 142(8):B13.

  8. Torpey ME, Nosrati A, Campton KL, Cohen SR. Ceftazidime-avibactam: A novel treatment for advanced hidradenitis suppurativa. J Invest Dermatol. 2022; 142(8):B12.

  9. Torpey ME, Nosrati A, Campton KL, Cohen SR. Impact of COVID-19 infection on hidradenitis suppurativa activity. J Invest Dermatol. 2022; 142(8):S46.

  10. Torpey ME, Nosrati A, Campton KL, Cohen SR. COVID-19 vaccine hesitancy in a cohort of hidradenitis suppurativa patients. J Invest Dermatol. 2022; 142(8):B13.

  11. Youssef M, Baugh E, Colvin A, Babbush KM, Andriano TM, Benesh G, Torpey ME, Nosrati A...Cohen SR, Petukhova L. Monogenic mutations implicate STAT1 in hidradenitis suppurativa pathologies. J Invest Dermatol. 2022;142(8):B22.

  12. Colvin A, Baugh E, Babbush KM, Andriano TM, Benesh G, Torpey ME, Nosrati A...Cohen SR, Petukhova L. Distribution of hidradenitis suppurativa monogenic etiologies in a racially diverse specialty clinic cohort. J Invest Dermatol. 2022;142(8):S80.

  13. Andriano TM, Babbush KM, Nosrati A, Benesh G, Hosgood HD, Cohen SR. Patient satisfaction with hidradenitis suppurativa televisits correlates with less severe disease. J Am Acad Dermatol. 2022;86(5):P1156-1159.

  14. Andriano TM, Babbush KM, Nosrati A, Benesh G, Hosgood HD, Cohen SR. 28544 Satisfaction and willingness to incorporate telemedicine for hidradenitis suppurativa. J Am Acad Dermatol. 2021;85(3):AB196.

  15. Vanden Brink H, Nosrati A, Ortiz-Flores AE, Tam A, Jarrett BY, Johnson L, Peppin AK, Lujan ME. Reliability and Agreement of Ultrasonographic Measures of the Ovarian Stroma: Impact of Methodology. J Ultrasound Med. 2021;10.1002/jum.15917.

  16. Nosrati A, Babbush K, Ghias MH, Pacific K, Hosgood HD, Cohen SR. Short-lived efficacy of ertapenem for refractory hidradenitis suppurativa. J Am Acad Dermatol. 2020;83(6):AB25.

  17. Babbush KM, Ghias MH, Nosrati A, Pacific KP, Hosgood HD, Cohen SR. Intravenous ertapenem therapy for advanced hidradenitis suppurativa. J Invest Dermatol. 2020;140(7):S66.

  18. Babbush KM, Waldman AR, Ghias MH, Nosrati A, Pacific KP, Lee DH, Cohen SR. Characterizing a cohort of pediatric patients with hidradenitis suppurativa. J Invest Dermatol. 2020;140(7):S59

  19. Babbush KM, Ghias MH, Nosrati A, Pacific KP, Reyes Gil M, Chaitowitz M, Hosgood HD, Cohen SR. The role of interleukin-6 in anemia associated with hidradenitis suppurativa. J Am Acad Dermatol. 2020;83(6):AB12.

  20. Pacific KP, Babbush KM, Johnston A, Nosrati A, Cohen SR. Tumor necrosis factor alpha levels predict hidradenitis suppurativa activity. J Am Acad Dermatol. 2020;83(6):AB61.

  21. Srivastava A, Shen D, Maron MI, Herman HS, Cohen BS, Nosrati A, Cortijo AR, Nosal S, Schoenbaum E. Implementation of Electronic Decision Support for Diabetic Care in a Student-Run Clinic. Cureus. 2020 Dec 22;12(12): e12219.

POSTER PRESENTATIONS

  1. Nosrati A, McCall MT, Shokrian N, Ch’en P, Andriano TM, Benesh G, Heibel HD, Hosgood HD, Campton KL, Cohen SR. Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa. International Symposium for Hidradenitis Suppurativa Advances, Miami, FL, October 2022.

  2. Torpey ME, Nosrati A, Romanelli S, Toker M, Ch’en P, Campton K, Cohen SR. Aggressive medical therapy is necessary in pediatric hidradenitis suppurativa disease management. International Symposium for Hidradenitis Suppurativa Advances, Miami, FL, October 2022.

  3. Rangu SA, Nosrati A, Torpey ME, Cohen SR. Anaerobic Microbes in hidradenitis suppurativa may predict more severe disease. International Symposium for Hidradenitis Suppurativa Advances, Miami, FL, October 2022.

  4. Toker, M, Torpey M, Nosrati A, Ch’en P, Campton K, Cohen SR. Efficacy of Oral Linezolid for Advanced Hidradenitis Suppurativa. International Symposium for Hidradenitis Suppurativa Advances, Miami, FL, October 2022.

  5. Nosrati A, Torpey ME, Ch’en PY, Ball G, Shokrian N, Andriano TM, Benesh G, Zhu, TR, Heibel HD, Hosgood DH, Campton KL, Cohen SR. Intravenous Ertapenem for Hidradenitis Suppurativa: Optimal Course Length, Efficacy, and Satisfaction. International Symposium for Hidradenitis Suppurativa Advances, Miami, FL, October 2022.

  6. Ch’en PY, Nosrati A, Torpey M, Mittal L, Campton KL, Cohen SR. Microbial Species Diversity in Patients with Hidradenitis Suppurativa during Ertapenem Therapy. International Symposium for Hidradenitis Suppurativa Advances, Miami, FL, October 2022.

  7. Ch’en PY, Torpey ME, Nosrati A, Toker M, Campton KL, Cohen SR. Patient Satisfaction with Intravenous Omadacycline as a Treatment for Hidradenitis Suppurativa. International Symposium for Hidradenitis Suppurativa Advances, Miami, FL, October 2022.

  8. Nosrati A, Torpey ME, Ch’en PY, Andriano TM, Heibel HD, Zhu TR, Campton KL, Cohen SR. Plastic Surgery for Hidradenitis Suppurativa: High Patient Satisfaction and Perception of Results. International Symposium for Hidradenitis Suppurativa Advances, Miami, FL, October 2022.

  9. Romanelli S, Nosrati A, Torpey ME, Ch’en PY, Toker M, Campton KL, Cohen SR. The Impact of Polycystic Ovary Syndrome on Hidradenitis Suppurativa Disease Severity. International Symposium for Hidradenitis Suppurativa Advances, Miami, FL, October 2022.

  10. Nosrati A, Torpey ME, Ball GD, Shokrian N, Campton KL, Cohen SR. COVID-19 Vaccine Immunity in Hidradenitis Suppurativa Patients Receiving TNF-alpha Inhibitors. Society for Investigative Dermatology Annual Conference. Portland, OR. May 2022.

  11. Nosrati A, Torpey ME, Campton KL, Cohen SR. Mental Health Professional Utilization within a Cohort of HS Patients. Society for Investigative Dermatology Annual Conference. Portland, OR. May 2022.

  12. Nosrati A, Torpey ME, Campton KL, Cohen SR. Opioid Use Disorder in a Population of Hidradenitis Suppurativa Patients. Society for Investigative Dermatology Annual Conference. Portland, OR. May 2022.

  13. Torpey ME, Nosrati A, Campton KL, Cohen SR. COVID-19 Vaccine Hesitancy in a Cohort of Hidradenitis Suppurativa Patients. Society for Investigative Dermatology Annual Conference. Portland, OR. May 2022.

  14. Torpey ME, Nosrati A, Cohen SR. Ceftazidime-Avibactam: A Novel Treatment for Advanced Hidradenitis Suppurativa. Society for Investigative Dermatology Annual Conference. Portland, OR. May 2022.

  15. Nosrati A, Torpey ME, Andriano TM, Ch’en PY, Dervieux T, Campton KL, Cohen SR. Association of hidradenitis suppurativa with a Crohn’s disease panel. Society for Investigational Dermatology Annual Conference. Portland, OR. May 2022.

  16. Torpey ME, Nosrati A, Campton KL, Cohen Sr. Impact of COVID-19 Infection on Hidradenitis Suppurativa Activity. Society for Investigational Dermatology Annual Conference. Portland, OR. May 2022.

  17. Antohi D, Andriano TM, Benesh G, Nosrati A, Torpey M, Hosgood HD, Cohen SR. Emergency department utilization in a population of hidradenitis suppurativa. Poster Presentation. 6th Annual Symposium on Hidradenitis Suppurativa Advances. Virtual. September 2021.

  18. Andriano TM, Babbush KM, Nosrati A, Benesh G, Cohen SR. Satisfaction and willingness to incorporate telemedicine for hidradenitis suppurativa. Poster Presentation. Annual Meeting of the American Academy of Dermatology. April 2021.

  19. Andriano TM, Babbush KM, Nosrati A, Benesh G, Cohen SR. Telemedicine for hidradenitis suppurativa during the COVID-19 pandemic. Poster Presentation. Annual Meeting of the American Academy of Dermatology. April 2021.

  20. Andriano TM, Babbush KM, Nosrati A, Benesh G, Cohen SR. Patient perspectives on telemedicine for hidradenitis suppurativa. Poster Presentation. 5th Annual Symposium on Hidradenitis Suppurativa Advances. Virtual. October 2020.

  21. Nosrati A, Babbush KM, Andriano TM, Benesh G, Cohen SR. Characterizing a cohort of hidradenitis suppurativa patients with developmental and intellectual disorders. Virtual Poster Presentation. 5th Annual Symposium on Hidradenitis Suppurativa Advances. October 2020.

  22. Babbush KM, Nosrati A, Ghias MH, Pacific KP, Andriano TM, Cohen SR. Intravenous ertapenem therapy for advanced hidradenitis suppurativa. Virtual Poster Presentation. 5th Annual Symposium on Hidradenitis Suppurativa Advances. October 2020.

  23. Pacific K, Babbush KM, Nosrati A, Hosgood HD, Cohen SR. Isotretinoin Therapy in the Treatment of Hidradenitis Suppurativa. Poster Presentation. 5th Annual Symposium on Hidradenitis Suppurativa Advances. October 2020.

  24. Babbush KM, Waldman AR, Ghias MH, Nosrati A, Pacific KP, Lee DH, Cohen SR. Characterizing a cohort of pediatric patients with hidradenitis suppurativa. Virtual Poster Presentation. Society for Pediatric Dermatology. July 2020.

  25. Babbush KM, Waldman AR, Ghias MH, Nosrati A, Pacific KP, Lee DH, Cohen SR. Characterizing a cohort of pediatric patients with hidradenitis suppurativa. Poster Presentation. Society for Investigational Dermatology Annual Conference. Scottsdale, AZ, USA. May 2020.

  26. Babbush KM, Ghias MH, Nosrati A, Reyes Gil M, Chaitowitz MH, Hosgood HD, Cohen SR. The role of interleukin-6 in anemia associated with hidradenitis suppurativa. Poster Presentation. 4th Annual Symposium on Hidradenitis Suppurativa Advances. Detroit, MI, USA. November 2019.

  27. Pacific KP, Babbush KM, Johnston A, Nosrati A, Cohen SR. Erythrocyte Sedimentation Rate, C- Reactive Protein, Interleukin-6, and Tumor Necrosis Factor Alpha Levels Predict Hidradenitis Suppurativa Severity. Poster Presentation. 4th Annual Symposium on Hidradenitis Suppurativa Advances. Detroit, MI, USA. November 2019.

  28. Nosrati A, Babbush KM, Ghias MH, Hosgood HD, Cohen SR. Short-lived efficacy of ertapenem for refractory hidradenitis suppurativa. Poster Presentation. 4th Annual Symposium on Hidradenitis Suppurativa Advances. Detroit, MI, USA. November 2019.

ORAL PRESENTATIONS

  1. Ch’en PY, Nosrati A, Torpey ME, Campton KL. Intravenous Ertapenem Improves Hidradenitis Suppurativa Outcomes in the Absence of Bacterial Growth. International Symposium for Hidradenitis Suppurativa Advances, Miami, FL, October 2022.

  2. Ch’en PY, Nosrati A, Torpey ME, Toker M, Campton KL, Cohen SR. Pilot Study of Intravenous Omadacycline Follow Up Therapy to Ertapenem for Hidradenitis Suppurativa. International Symposium for Hidradenitis Suppurativa Advances, Miami, FL, October 2022.

  3. Nosrati A, Cohen SR. Under-recognized morphologies and pathologies of hidradenitis suppurativa. Albert Einstein College of Medicine Research Fellowship Conference. Virtual. February 2022.

  4. Nosrati A, Torpey ME, Andriano TM, Jacobson MI, Cohen SR. Under-recognized knife-like lesions in advanced hidradenitis suppurativa. Poster Presentation. 11th Conference of the European Hidradenitis Suppurativa Foundation. Virtual. February 2022.

  5. Colvin A, Baugh E, Babbush K, Soliman Y, Shaw F, Ghias M, Andriano TM, Torpey ME, Nosrati A, DeWan A, Leal SM, Goldstein D, Cohen S, Petukhova L. Distribution of monogenic etiologies in a racially diverse hidradenitis suppurativa (HS) cohort. Virtual Oral Presentation. 11th Virtual Conference of the European Hidradenitis Suppurativa Foundation. 2022.

  6. Andriano TM, Benesh G, Pattison L, Nosrati A, Torpey M, Hosgood HD, Cohen SR. Elucidating factors associated with isotretinoin response in hidradenitis suppurativa. Oral Presentation. 6th Annual Symposium on Hidradenitis Suppurativa Advances. Virtual. September 2021.

  7. Benesh G, Andriano TM, Nosrati A, Torpey M, Hosgood HD, Cohen SR. Efficacy and patient perspectives of ertapenem for severe hidradenitis suppurativa. Oral Presentation. 6th Annual Symposium on Hidradenitis Suppurativa Advances. Virtual. September 2021.

  8. Ball G, Benesh G, Andriano TM, Nosrati A, Torpey M, Hosgood HD, Cohen SR. Assessing health literacy in a sample of patients with hidradenitis suppurativa. Oral Presentation. 6th Annual Symposium on Hidradenitis Suppurativa Advances. Virtual. September 2021.

  9. Shokrian N, Benesh G, Andriano TM, Nosrati A, Torpey M, Hosgood HD, Cohen SR. Evaluating adalimumab efficacy based on body mass index for hidradenitis suppurativa. Oral Presentation. 6th Annual Symposium on Hidradenitis Suppurativa Advances. Virtual. September 2021.

  10. Colvin A, Baugh E, Babbush KM, Andriano TM, Nosrati A, DeWan A, Leal S, Goldstein D, Cohen SR, Petukhova L. Distribution of hidradenitis suppurativa monogenic etiologies in a racially diverse specialty clinic cohort. Oral Presentation. 6th Annual Symposium on Hidradenitis Suppurativa Advances. Virtual. September 2021.

  11. Babbush KM, Ghias MH, Nosrati A, Pacific KP, Hosgood HD, Cohen SR. Intravenous ertapenem therapy for advanced hidradenitis suppurativa. Virtual Oral Presentation. Society for Investigational Dermatology Annual Conference. May 2020.

  12. Babbush KM, Ghias MH, Nosrati A, Pacific KP, Reyes Gil M, Chaitowitz MH, Hosgood HD, Cohen SR. The role of interleukin-6 in anemia associated with hidradenitis suppurativa. Virtual Oral and Poster Presentation. Annual Meeting of the American Academy of Dermatology. March 2020.

  13. Nosrati A, Babbush KM, Ghias MH, Pacific KP, Hosgood HD, Cohen SR. Short-lived efficacy of ertapenem for refractory hidradenitis suppurativa. Virtual Oral and Poster Presentation. Annual Meeting of the American Academy of Dermatology. March 2020.

  14. Pacific KP, Babbush KM, Johnston A, Nosrati A, Cohen SR. Tumor Necrosis Factor Alpha Levels Predict Hidradenitis Suppurativa Activity. Virtual Oral and Poster Presentation. Annual Meeting of the American Academy of Dermatology. March 2020.